Hyderabad, India, April 7, 2026
Phase 3 Trial Confirms Biosimilar Equivalence
In a significant milestone for biosimilar drug development, CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has reported positive Phase 3 topline results for its investigational omalizumab biosimilar BP11, demonstrating comparable efficacy and safety to the reference biologic Xolair® (omalizumab). The global multicenter trial, conducted across 608 patients at nearly 80 sites in Europe and India, successfully met all primary endpoints in patients with chronic spontaneous urticaria (CSU) at the 300 mg dose.
The study evaluated changes in the ISS7 (7-point Itch Severity Score) at Week 12, a key regulatory endpoint widely accepted by both the U.S. FDA and European Medicines Agency (EMA). The results confirmed biosimilar equivalence, with confidence intervals falling within predefined margins, reinforcing BP11’s potential as a high-quality, cost-effective alternative to Xolair in treating IgE-mediated allergic diseases.
Strong Clinical Outcomes and Mechanistic Relevance
BP11 is designed as a monoclonal antibody targeting immunoglobulin E (IgE), a central mediator in allergic inflammation pathways. By blocking IgE, the therapy helps reduce hypersensitivity reactions, making it effective across multiple conditions including allergic asthma, CSU, and chronic rhinosinusitis with nasal polyps (CRSwNP). In the Phase 3 study, secondary endpoints, including relative potency and dose-response consistency, were also successfully met, further validating the biosimilar’s clinical performance and pharmacodynamic comparability.
Advertisement
The demonstration of similar efficacy across both primary and secondary endpoints highlights BP11’s ability to replicate the therapeutic benefits of the originator biologic, a critical requirement for biosimilar approval pathways. These results are particularly important in the context of rising demand for affordable biologics, as biosimilars play a key role in improving patient access to advanced therapies while reducing healthcare costs.
Regulatory Strategy and Market Expansion Plans
Building on these strong clinical outcomes, CuraTeQ has announced plans to submit regulatory filings for BP11 to both the U.S. FDA and EMA by the end of Q2 2026, marking the next step toward global commercialization. The company aims to pursue approvals across multiple indications, leveraging the totality of evidence generated in clinical trials. According to company leadership, the narrow confidence intervals and robust dataset validate the clinical strategy and execution quality, positioning BP11 as a competitive entrant in the global omalizumab biosimilar market.
With Xolair being a blockbuster biologic, the introduction of BP11 is expected to create significant market opportunities, particularly in regions where cost remains a barrier to biologic therapy adoption. The expansion into indications such as allergic asthma and CRSwNP further enhances BP11’s commercial potential and therapeutic reach.
Advancing Access to Affordable Biologic Therapies
The successful Phase 3 results for BP11 highlight the growing importance of biosimilars in transforming global healthcare systems, particularly in addressing the cost challenges associated with biologic treatments. Allergic diseases such as CSU and asthma affect millions of patients worldwide, many of whom lack access to high-cost biologic therapies. By offering a clinically equivalent and more affordable alternative, BP11 has the potential to expand treatment accessibility and improve patient outcomes.
The development also reflects Aurobindo Pharma’s broader strategy of strengthening its biopharma portfolio and global footprint, leveraging CuraTeQ’s expertise in biosimilar development, clinical research, and regulatory execution. As regulatory submissions progress and approvals are secured, BP11 could emerge as a key player in the immunology biosimilars market, contributing to the ongoing shift toward cost-effective, high-quality biologic therapies.
Source: CuraTeQ Biologics press release
